Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Aug 2, 2023
Discovery & Translation
TRIM11 for tauopathies; plus TCRs that recognize multiple antigens and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 19, 2023
Data Byte
ADCs overtake mAbs in AACR’s first-in-human abstracts
BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023
BioCentury | Feb 10, 2023
Discovery & Translation
Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more
BioCentury's roundup of translational news
BioCentury | Dec 10, 2022
Discovery & Translation
Blocking FXR for COVID-19; plus Athira’s small molecule for ALS and more
BioCentury’s roundup of translational news
BioCentury | Nov 21, 2022
Data Byte
Signs Western companies are turning to China for cancer innovation
Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets
BioCentury | Nov 9, 2022
Regulation
Nov. 8 Quick Takes: FDA request could extend review of BioMarin’s hemophilia therapy
Plus Sanofi’s latest AI deal taps Insilico and updates from Kronos, Marinus and more
BioCentury | Oct 24, 2020
Translation in Brief
UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more
BioCentury’s roundup of translational news
BioCentury | Aug 25, 2020
Finance
$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial
After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to fund the cancer therapy’s registrational trial, slated for 2021. The funding will also
BioCentury | Jul 17, 2020
Deals
Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators
Kronos buys Gilead’s portfolio of SYK inhibitors, carrying the preclinical cancer play to the cusp of Phase III
Items per page:
1 - 10 of 59